Side effects decide whether people stay on a drug long enough for it to work, and the newest obesity medicines show how much they can differ. In the Phase 3 SYNCHRONIZE-2 trial reported on October 1, 2026, 18% of people on Boehringer's survodutide stopped treatment because of gastrointestinal side effects, versus 1.2% on placebo. Lilly's TRIUMPH-2 trial of retatrutide, published in The Lancet in September 2026, recorded dysesthesia, an abnormal skin sensation, in 4.5% to 7.3% of patients versus 0.7% on placebo.
Some signals come from weaker evidence. At the EADV dermatology congress in October 2026, a self-reported, cross-sectional study found that GLP-1 users described nail detachment about four times as often as nonusers, a link that does not prove cause.
Stories here cover trial safety data and emerging reports. See #glp-1, #drug-safety, and #retatrutide.
A woman with type 2 diabetes and severe obesity who was also taking insulin and the diuretic torsemide developed loss of appetite, weakness, and drowsiness 10 days after starting tirzepatide, with a blood sodium of 104 mmol/L and lab results consistent with SIADH, a physician at Apollo Specialty Hospital in Bengaluru reported in the Indian Journal of Pharmacology. She improved with fluid restriction and hypertonic saline. A single case shows a timing association, not cause, and the author suggests checking electrolytes in patients with significant stomach symptoms or poor intake.
In Vanda Pharmaceuticals' placebo-controlled Phase 3 Study 3601, people given a single 1 mg semaglutide dose without the usual dose ramp-up vomited less often on the NK-1 blocker tradipitant: 43.0% (61 of 142) versus 58.5% (96 of 164) on placebo, P = .006, HCPLive reported. The key secondary endpoint of vomiting plus moderate or worse nausea fell to 33.1% from 50.6%. Vanda plans to meet the FDA in 2027 before filing a supplemental application; the trial did not test tirzepatide or the usual gradual dosing.
Western University researchers in Ontario reported in Pharmacoepidemiology and Drug Safety on October 27, 2026 an analysis of FDA Adverse Event Reporting System data from 2018 to 2024. Panic attacks appeared in 0.26% of 33,267 semaglutide reports versus 0.05% for dulaglutide and empagliflozin (adjusted reporting odds ratios 2.82 and 2.75), but the adjusted signal before July 1, 2023 was not significant, and panic reports per 10,000 semaglutide reports rose from 6.7 in 2018-2022 to 42.0 in 2023-2024. Across 12 trials and comparison studies, the team found no consistent rise in panic or anxiety, and says the pattern fits notoriety bias, where publicity drives reporting.
Washington University School of Medicine researchers reported in HAND on October 26, 2026 a TriNetX study of 11,158 matched pairs of adults who had bariatric surgery between January 2015 and February 2026, with or without a GLP-1 drug. Over a median year of follow-up, GLP-1 users had more new carpal tunnel syndrome diagnoses (risk ratio 1.63) and cubital tunnel syndrome diagnoses (2.10) and more nerve-conduction testing (1.43), but carpal tunnel release surgery rates did not differ significantly. The GLP-1 group was younger and had a lower BMI at baseline, and the authors say more work is needed on mechanisms and monitoring.
Endocrinologists at Zhongnan Hospital of Wuhan University described in Frontiers in Endocrinology on October 22, 2026 a 28-year-old man with obesity and no known high blood sugar who injected tirzepatide on his own, lost 15 kg over about three months, and was then diagnosed with GADA antibody-positive type 1 diabetes presenting as diabetic ketoacidosis, with an HbA1c of 10.8% and GADA above 2,000 IU/mL. On insulin, his HbA1c fell to 6.7% at three months. The authors say a single case cannot show that tirzepatide or stopping it caused the diabetes, and that the high HbA1c suggests high blood sugar came first; their message is to consider autoimmune diabetes when unexplained hyperglycemia, continued weight loss, or ketoacidosis appears during self-directed weight-loss treatment.
Researchers at Istanbul Medipol University argued in a narrative review in Diabetes, Obesity and Metabolism, published October 22, 2026, that the major liraglutide (SCALE), semaglutide (STEP), and tirzepatide (SURMOUNT) obesity programs captured nausea through investigator-recorded adverse events coded in MedDRA rather than any validated, symptom-specific patient-reported tool, while the same programs used detailed quality-of-life questionnaires. They suggest this gap may help explain why real-world persistence on GLP-1 drugs falls short of what trial tolerability figures predict, and they outline what a dedicated nausea measure would need to capture. The paper is an argument based on published methods, not new data.
University of Pennsylvania and Boston Children's Hospital researchers reported in a JAMA Network Open research letter on October 14, 2026 that they used large language models to read 148,640 retatrutide-related Reddit posts and comments from 27 communities, posted from 2021 to 2025, and mapped symptoms from 7,823 users who described current use of the unapproved drug. The most common terms were increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%), nausea (11.6%), and insomnia (6.1%), and 4.8% mentioned a faster heart rate, a profile in which stomach symptoms were less dominant than in Lilly's trials. The authors called the findings hypothesis-generating, since what users injected, how much, and with what else cannot be verified.
A review by a Chung-Ang University dermatologist, published October 14, 2026 in Aesthetic Surgery Journal, pooled 46 reports on facial hollowing and sagging during GLP-1 weight loss. Serial imaging in 20 patients showed a median 9% loss of midface volume, more in superficial than deep fat (11% vs 7%), about 7% per 10 kg of weight lost, and a survey of 1,226 people linked more facial volume loss to greater percentage weight loss. Similar changes follow bariatric surgery, so the author concluded that weight-loss deflation on top of normal aging, not a drug-specific effect, explains most of it, and that evidence for cosmetic treatments is limited.
Physicians at University Hospital Zurich described in BMJ Case Reports on October 7, 2026 a woman in her mid-20s who was admitted after five days of nausea, repeated vomiting, and loose stools that did not stop with IV fluids and three anti-nausea drugs. After repeated questioning, she said that in a wellness setting a self-described life coach with no medical training had given her four weekly, rising doses of an unverified product said to contain retatrutide, Eli Lilly's experimental GLP-1, GIP, and glucagon drug; she had not thought of the shots as medicine. She improved two days after admission and recovered within a week, a standard scale rated the product as the probable cause, and the authors urge doctors to ask directly about injections, peptides, and research chemicals.
A cross-sectional, case-control study presented at the European Academy of Dermatology and Venereology Congress in Vienna (September 30 to October 3, 2026) compared 575 GLP-1 receptor agonist users with 1,329 people with type 2 diabetes, obesity, or both who had never taken the drugs, in France, the U.S., Brazil, and Mexico. Users reported nail detachment far more often (39% vs. 9%), along with nail discoloration (46% vs. 17%) and unusual hair loss (50% vs. 34%); after adjustment, nail detachment and discoloration remained roughly two to three times as frequent. The symptoms were self-reported, about half of users said they had nail problems before treatment, and the design cannot show that the drugs cause these changes; Gizmodo reported that the work was funded by Pierre Fabre.
DistilINFO and an Endocrine review published May 1 consolidated the clinical literature on accelerated facial aging in patients on GLP-1 receptor agonists. A 2025 Vanderbilt study of 20 patients reported a median 9% midface volume loss overall, or about 7% per 10 kg of total weight loss, with GLP-1-mediated lipolysis disproportionately affecting superficial and medial cheek fat pads. The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% increase in face-grafting procedures in the past year tied to the trend, and one in four surgeons expects continued growth in nonsurgical demand (fillers, microneedling, RF, CO2 laser). Mechanistic work in Endocrine adds a possible direct effect on adipose-derived stem cells beyond rapid fat loss alone.
Researchers analyzed 410,198 Reddit posts mentioning semaglutide or tirzepatide, finding 43.5% of 67,008 self-reported users described at least one side effect extending beyond clinical trial data.